The oxycodone market is driven by an increase in the number of patients suffering from terminally ill diseases.

Market Size – USD 4.68 Billion in 2018, Market Growth - CAGR of 4.6%, Market Trends – Expanding occurrence of diseases that cause chronic pain, such as postsurgical pain, back pain, cancer and fibromyalgia is boosting the market.

NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- The Oxycodone Market is estimated to grow from USD 4.68 Billion in 2018 to USD 6.78 Billion by 2026, at a CAGR of 4.6%, during the forecast period. The oxycodone market is driven by an increase in the number of patients suffering from terminally ill diseases such as cancer and HIV and a high increase in the prescription of post-operative pain medication.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/1286

Cancer's growing commonness, Parkinson's disease, and rheumatic diseases drive the growth of the market. The use of oxycodone to relieve post-operative pain under different medical conditions fuels the growth of the market.

Increasing concern about oxycodone abuse, however, is curbing market growth. However, less addictive oxycodone drugs approved by the FDA for adults and children are likely to open new gateways in the forecast period for the growth of Oxycodone Market.

Further key findings from the report suggest

• The Oxycodone Market is estimated to grow from USD 4.68 Billion in 2018 to USD 6.78 Billion by 2026, at a CAGR of 4.6%, during the forecast period. The oxycodone market is driven by an increase in the number of patients suffering from terminally ill diseases such as cancer and HIV and a high increase in the prescription of post-operative pain medication.
  
  
• The market for short acting oxycodone is expected to hold the largest market share at USD 5.09 Billion by 2026, at a CAGR of 5.5% during the forecast period. An increase in pharmaceutical companies new drug applications and the number of products in the pipeline are driving the market for oxycodone. Other formulations are coming up on the market, such as controlling the release of drugs to improve pain management.

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/oxycodone-market

• Based on routes of administration, the oral segment is expected to hold the largest market share and is expected to reach USD 2.98 Billion by 2026, at a CAGR of 5.8% during the forecast period. Oxycodone is only approved for mouth use in the United States, which is available as tablets and oral solutions. However, oxycodone parenteral formulations (brand name OxyNorm) are also available worldwide and are widely used in Europe.
  
  
• The market for hospital pharmacies is expected to reach USD 3.05 Billion by 2026, at a CAGR of 6.1% during the forecast period. The large scale development of specialty hospitals with increasing purchasing power is driving oxycodone products to be adopted more quickly. Another driver for the oxycodone market is the consolidation of large healthcare providers coupled with increased penetration of healthcare insurance.
  
  
• The market for North America is expected to reach USD 2.8 Billion by 2026, at a CAGR of 4.9% during the forecast period due to the increase in spending on healthcare market and the dominance of geriatric populations with terminal conditions such as rheumatoid arthritis is increasing, which will foster market growth.
  
  
• The major players in the market are Johnson & Johnson (US), Sanofi (France), Pfizer (US), Purdue Pharma (US), Endo International (Ireland), Teva Pharmaceuticals (Israel), Hikma Pharmaceuticals (UK), Mallinckrodt (UK), Mylan (US), Sun Pharmaceutical (India), Impax Laboratories (US), Indivior (UK) and others.

Order Now:   https://www.reportsanddata.com/checkout-form/1286

Segments covered in the report:

This report forecasts volume and revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2016 to 2026. For the purpose of this study, Reports and Data have segmented the market on the basis of type, routes of administration, application, distribution channel and regional analysis.

Type (Kilo Tons) (Revenue, USD Million; 2016-2026)

• Short Acting Oxycodone
  
  
• Long Acting Oxycodone

Routes of Administration (Kilo Tons) (Revenue, USD Million; 2016-2026)

• Oral
  
  
• Sublingual
  
  
• Intramuscular
  
  
• Intravenous
  
  
• Intranasal
  
  
• Subcutaneous
  
  
• Transdermal
  
  
• Rectal
  
  
• Epidural

Distribution (Kilo Tons) (Revenue, USD Million; 2016-2026)

• Hospital Pharmacies
  
  
• Retail Pharmacies
  
  
• Others

Application (Kilo Tons) (Revenue, USD Million; 2016-2026)

• De-Addiction
  
  
• Pain Management

Region (Kilo Tons) (Revenue, USD Million; 2016-2026)

• North America
  
  
  • U.S
    
    
• Europe
  
  
  • France
    
    
  • UK
    
    
• Asia Pacific
  
  
  • China
    
    
  • India
    
    
  • Japan
    
    
• Latin America
  
  
  • Brazil

• Middle East & Africa

Browse more reports of Pharma and Healthcare category at:  https://www.reportsanddata.com/report/category/pharma-and-healthcare

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web: www.reportsanddata.com

Direct Line: +1-800-819-3052

E-mail: sales@reportsanddata.com